00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
18:07 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis In vitro and mouse studies identified a chemokine-targeting single-chain variable fragment (scFv)-based fusion protein that could help treat arthritis. Screening of a scFv library for binding to various human and mouse chemokines, engineering...
00:53 , Mar 7, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on CLEC1A could help predict the risk of Aspergillus infections in stem cell transplant recipients. In 310 stem cell transplant donors and matched recipients, genomic sequencing and cumulative incident analysis identified...
22:54 , Nov 17, 2017 |  BioCentury  |  Finance

Stepwise progress

After six years and four Phase I trials ImmusanT Inc. has finally nailed down the optimal dose regimen for celiac disease vaccine Nexvax2 and is ready to take the leap into Phase IIb testing with...
19:02 , May 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
21:38 , Jan 27, 2017 |  BC Week In Review  |  Company News

SATT Sud-Est, Immune Pharmaceuticals deal

Immune Pharmaceuticals received an exclusive sublicense from French technology transfer office SATT Sud-Est to develop, manufacture and commercialize antibodies targeting the tumor microenvironment and angiogenic factors. The monospecific and bispecific antibodies will be developed under...
19:13 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

Neflamapimod: Ph IIa Study 303 data

The double-blind, U.S. Phase IIa Study 303 in 8 evaluable patients ages 60-85 with mild cognitive impairment (MCI) due to AD or mild AD showed that twice-daily 40 and 125 mg oral neflamapimod improved mean...
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mammalian target of rapamycin (mTOR; FRAP; RAFT1); interleukin-8 (IL-8; CXCL8)

Cancer INDICATION: Liver cancer Cell culture studies suggest combining doxorubicin with mTOR inhibitors could help treat hepatocellular carcinoma (HCC). In a xenograft mouse model of HCC, the generic chemotherapy doxorubicin and the generic mTOR inhibitor...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

VBI Vaccines preclinical data

In an ex vivo model of CMV-positive GBM, VBI-1901 recruited and activated dendritic cells as measured by induction of interleukin-8 (IL-8; CXCL8 ) and macrophage inflammatory protein-1 alpha ( CCL3 ; MIP1A ). The product...